Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Methodist Health System Research Team
Summary
This ongoing observational study at Methodist Health System is collecting real-world data on treatment responses, survival outcomes, and adverse events in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with peptide receptor radionuclide therapy (PRRT). The study tracks patients for up to 7 years post-procedure.
Clinical Significance
As PRRT with ¹⁷⁷Lu-DOTATATE becomes increasingly adopted for neuroendocrine tumors, real-world outcome data beyond clinical trials is essential. This registry will help optimize patient selection and identify predictors of response to peptide-based radioligand therapy.
Trial Details
- Design: Prospective observational cohort
- Population: GEP-NET patients with metastatic/locally advanced inoperable disease
- Inclusion criteria: Ki67 <20%, DOTATATE PET-positive, progressive disease on octreotide
- Primary outcomes: Demographics, tumor data, biomarkers (chromogranin A, pancreastatin), imaging response, OS, TTP
- Follow-up: Up to 7 years from first PRRT
- Status: Actively recruiting, estimated completion June 2026
Clinical Implications
PRRT is a key treatment modality for well-differentiated GEP-NETs. This real-world registry will complement the landmark NETTER-1 trial data by providing long-term outcomes in a broader patient population treated in community oncology settings.
Aiheeseen liittyvä tutkimus
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…